THE DEAL, AT A GLANCE

AnaCardio

2/4 reviewed

AnaCardio

AnaCardio develops new drug treatments for heart failure.

AnaCardio raised Series B, announced 2026-09-29

Source-provided image · View source ↗

01What it doesAnaCardio develops new drug treatments for heart failure.Source-grounded · automated review · Explore ↗

Checked 2026-10-08 · Review due 2026-10-15

AnaCardio, a clinical-stage biopharmaceutical company…

02Who is involvedBacked by Novo Holdings, Pureos Bioventures, Sound Bioventures</strong>, Karolinska InstitutetFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

03What happenedAnaCardio raised Series B, announced 2026-09-29From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

04Why it mattersIts work matters because it focuses on treating heart failure.Interpretation · Explore ↗

Checked 2026-10-08 · Review due 2026-10-15

developing novel therapies for heart…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

AnaCardio · Financing Record

Explore source-linked visual explanations for AnaCardio. Unsupported claims are withheld while source review continues.

Record 13028 · Recorded date: 2026-09-29